Loading...
XIDX
DVLA
Market cap103mUSD
Nov 12, Last price  
1,655.00IDR
Name

Darya-Varia Laboratoria Tbk PT

Chart & performance

D1W1MN
XIDX:DVLA chart
P/E
11.31
P/S
0.83
EPS
146.38
Div yield, %
3.93%
Shrs. gr., 5y
—
Rev. gr., 5y
4.05%
Revenues
2.23t
+6.90%
869,170,910,000929,196,665,000972,297,437,0001,087,379,869,0001,101,684,170,0001,103,821,775,0001,306,098,136,0001,451,356,680,0001,575,647,308,0001,699,657,296,0001,813,020,278,0001,829,699,557,0001,900,893,602,0001,917,041,442,0001,890,887,506,0002,087,601,399,0002,231,748,811,000
Net income
163.95b
+5.00%
72,272,233,000110,880,522,000120,915,340,000148,909,089,000125,796,473,00080,929,476,000107,894,430,000152,083,400,000162,249,293,000200,651,968,000221,783,249,000162,072,984,000146,505,337,000149,375,011,000146,336,365,000156,147,303,000163,947,127,000
CFO
201.14b
-39.37%
5,688,757,000130,614,145,00072,518,015,000119,207,439,000106,931,180,000104,436,317,000214,166,823,000187,475,539,000230,738,193,00026,628,428,000272,538,844,000106,583,179,000435,333,430,000-16,060,100,000109,185,785,000331,762,800,000201,144,418,000
Dividend
Jun 30, 202664 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PT Darya-Varia Laboratoria Tbk is an Indonesian enterprise dedicated to the production and commercialization of pharmaceutical goods and cosmetic items. Its operations are organized into three primary divisions: prescription medications, consumer health products, and services for export and contract manufacturing. The company offers a comprehensive selection of both prescribed and over-the-counter health solutions, addressing categories like antibiotics, antiparasitics, antiseptics, antifungals, treatments for coughs and colds, cardiovascular conditions, central nervous system disorders, gastrointestinal and liver ailments, somatic issues, vitamins and dietary supplements, women's health, ear care, and dermatological concerns. Beyond its domestic activities, the firm also distributes its products internationally to nations such as Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. Established in 1976, PT Darya-Varia Laboratoria Tbk is headquartered in Jakarta, Indonesia, and functions as a subsidiary of Blue Sphere Singapore Pte. Ltd.

Key people

Clinton Andrew Hess
President Commissioner · since 2019
Jose Sumpaico Romana
President Director · since 2020
Eric Albert Gotuaco
Vice President Commissioner · since 2019
Ian Kloer
Vice President Director · since 2020
Maria Christina Carnay
Director · since 2020
Carlos Nava
Director · since 2009
Angelito Celso Racho
Director · since 2010
Yustina Endang Setyowati
Independent Director · since 2017
Widya Olivia Tobing
Corporate Secretary · since 2017
Marlia Hayati Goestam
Commissioner · since 2020
Mariano John Tan
Commissioner · since 2010
Sancoyo Antarikso
Independent Commissioner · since 2021
Sonny Kalona
Independent Commissioner · since 2010
IPO date
Nov 11, 1994
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT